<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601156</url>
  </required_header>
  <id_info>
    <org_study_id>PCAR</org_study_id>
    <nct_id>NCT03601156</nct_id>
  </id_info>
  <brief_title>Preoperative Intraarterial Chemoembolization Combined With Radiotherpy in Locally Advanced Rectal Cancer</brief_title>
  <acronym>PCAR</acronym>
  <official_title>Multi-center Study of Preoperative Intraarterial Chemoembolization Combined With Radiotherpy in the Management of Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compared to postoperative chemotherapy combined with radiotherapy, preoperative chemotherapy
      combined with radiotherapy shows higher sphincter preservation rate and lower local
      recurrence rate in locally advanced rectal cancer. The purpose of this study is to evaluate
      the response and prognosis of intraarterial chemoembolization and intravenous infusion
      chemotherapy in patients with rectal T3-T4 and/or N+ rectal cancer before operation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR)</measure>
    <time_frame>pathologic examination following surgery, at aproximately 9-10 weeks or after preoperative intraarterial chemoembolization plus radiotherpy</time_frame>
    <description>Pathological complete response (pCR) was determined on tumor resection specimens after completion of neoadjuvant therapy, and was defined as no evidence of residual invasive and ductal disease in the rectum and lymph nodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Sphincter Preservation Rate</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Following surgery, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>the first day of treatment to death or last survival confirm date; assesed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Down Staging Rate</measure>
    <time_frame>Until surgery at 8-9 weeks post chemoradiation plus radiation (which is 4-5 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Until surgery at 8-9 weeks post chemoradiation plus radiation (which is 4-5 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Postoperative Complication</measure>
    <time_frame>Until surgery at 8-9 weeks post chemoradiation plus radiation (which is 4-5 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>NATACE-RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Oxaliplatin 130mg/m2 intraarterial chemoembolization on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA &lt; 1.25 mm2 receive 80 mg/day; 1.25 mm2 &lt; BSA &lt; 1.5mm2 recive 100 mg/day, BSA&gt;1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NACT-RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive Oxaliplatin 130mg/m2 intravenous chemotherapy on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA &lt; 1.25 mm2 receive 80 mg/day; 1.25 mm2 &lt; BSA &lt; 1.5mm2 recive 100 mg/day, BSA&gt;1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intraarterial chemoembolization</intervention_name>
    <arm_group_label>NATACE-RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intravenous chemotherapy</intervention_name>
    <arm_group_label>NACT-RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of rectal cancer, Stage IV.

          -  Males or females between 18 Years to 75 Years.

          -  No prior cisplatin-based chemotherapy or radiotherapy.

          -  Performance status of 0～2 on the ECOG criteria.

          -  Adequate hematologic (Leukocyte count &gt;= 4,000/uL, neutrophil count &gt;= 1,500/uL,
             hemoglobin &gt;= 10 g/dL, platelets &gt;= 100,000/uL), hepatic (AST &amp; ALT =&lt; upper normal
             limit(UNL)x1.5, bilirubin level =&lt; UNLx1.5), and renal (creatinine =&lt; UNL x1.5 or
             creatinine clearance rate ≥60 ml/min) function.

          -  Patient can take oral medicine

          -  Patient compliance that allow adequate follow-up. Informed consent from patient or
             patient's relative.

        Exclusion Criteria:

          -  Patient with allergic to S-1 or ingredient of Oxaliplatin

          -  Patient with Peripheral neuropathy

          -  Diagnosed fibrosis of lung;pulmonary fibrosis or interstitial pneumonia within 28
             days.

          -  Medically uncontrolled serious heart, renal failure, liver failure, hemorrhagic peptic
             ulcer, paralysis of intestine , ileus, poor controlled diabetes.

          -  Enrollment in other study.

          -  Pregnant or breast-feeding.

          -  Seriously psyche or intelligence problem.

          -  Inability to comply with protocol or study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dong Wang, PH.D.</last_name>
    <phone>86-23-68757151</phone>
    <email>dongwang64@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Daping Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Wang, PH.D.</last_name>
      <phone>86-23-68757151</phone>
      <email>dongwang64@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Dong Wang, PH.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing Zhongshan Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhixiang Yang, M.D.</last_name>
      <phone>86-13032372491</phone>
    </contact>
    <investigator>
      <last_name>Zhixiang Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangjin Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debing Xiang, M.D.</last_name>
      <phone>86-13320336639</phone>
    </contact>
    <investigator>
      <last_name>Debing Xiang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Dong Wang</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>intraarterial chemoembolization</keyword>
  <keyword>radiotherpy</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Tegafur Gimeracil and Oteracil Porassium Capsule</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

